Q&A: Merck KGaA Global Head Of Medical Affairs On Pipeline Persistence
Maria Rivas has been in post as Merck KGaA’s global head of medical affairs for just over a month. She talks to Scrip about her immediate priorities, and the Darmstadt-based company’s potential in immunotherapies and oncology.
You may also be interested in...
With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.
Luciano Rossetti says Germany's Merck is likely to partner M7824 bifunctional immunotherapy, and go solo with tepotinib.
CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.